Novartis building Chinese presence with vaccines acquisition and R&D investment
This article was originally published in Scrip
Executive Summary
Novartis has become the latest multinational to set its sights on the fast-growing vaccines market in China, where it has unveiled plans to acquire a Chinese manufacturer, and is also investing $1 billion over the next five years to build up its R&D operations in the country.